中华肝胆外科杂志
中華肝膽外科雜誌
중화간담외과잡지
CHINESE JOURNAL OF HEPATOBILIARY SURGERY
2010年
11期
809-811
,共3页
癌,胆囊%晚期胆囊癌%化疗方案%生长抑素
癌,膽囊%晚期膽囊癌%化療方案%生長抑素
암,담낭%만기담낭암%화료방안%생장억소
Advanced gallbladder carcinoma%Chemotherapy regimen%Somatostatin
化疗等综合性治疗为提高晚期胆囊癌病人总体生存状况的主要手段,选择胆囊癌敏感的化疗方案则为研究的重点.2010年至2011年,以上海交通大学医学院附属新华医院普外科为首的全国31个临床中心将入组260例晚期胆囊癌病人,采用随机对照开放的方式对晚期胆囊癌化疗新方案(Cisplatin+epirubicin+5-FU+LV联合SST)进行有效性及安全性的评价.目前此研究已获得美国国立卫生研究院临床试验注册平台批准,并成功入组30余例病人.此次临床试验将为晚期胆囊癌临床化疗提供可信的循证依据,成为我国乃至世界范围内胆囊癌化疗大型临床研究的重要组成部分之一.
化療等綜閤性治療為提高晚期膽囊癌病人總體生存狀況的主要手段,選擇膽囊癌敏感的化療方案則為研究的重點.2010年至2011年,以上海交通大學醫學院附屬新華醫院普外科為首的全國31箇臨床中心將入組260例晚期膽囊癌病人,採用隨機對照開放的方式對晚期膽囊癌化療新方案(Cisplatin+epirubicin+5-FU+LV聯閤SST)進行有效性及安全性的評價.目前此研究已穫得美國國立衛生研究院臨床試驗註冊平檯批準,併成功入組30餘例病人.此次臨床試驗將為晚期膽囊癌臨床化療提供可信的循證依據,成為我國迺至世界範圍內膽囊癌化療大型臨床研究的重要組成部分之一.
화료등종합성치료위제고만기담낭암병인총체생존상황적주요수단,선택담낭암민감적화료방안칙위연구적중점.2010년지2011년,이상해교통대학의학원부속신화의원보외과위수적전국31개림상중심장입조260례만기담낭암병인,채용수궤대조개방적방식대만기담낭암화료신방안(Cisplatin+epirubicin+5-FU+LV연합SST)진행유효성급안전성적평개.목전차연구이획득미국국립위생연구원림상시험주책평태비준,병성공입조30여례병인.차차림상시험장위만기담낭암림상화료제공가신적순증의거,성위아국내지세계범위내담낭암화료대형림상연구적중요조성부분지일.
Comprehensive therapy is the leading method to improve the overall survival for patients with advanced gallbladder cancer, especially the study of new chemotherapy regimen are on demand.From 2010 to 2011, a phase Ⅲ study of new chemotherapy regimen in the treatment of advanced gallbladder carcinoma would be undertaken nationwide to assess the clinical outcome and safety, in 31 clinical centers led by the department of General Surgery of Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, and a total of 260 patients would be accrued for this study.Chemotherapy consists of 2 regimes, conventional regime(cisplatin, epirubicin, and 5-fluorouracil, leucovorin)and new regime(conventional regime plus somatostatin).At present, the study has been approved by Clinical Trial Registration Platform of National Institutes of Health in U.S.A., and more than 30 patients are rolling in the study.The clinical trial could provide the high-quality evidence of EBM(evdence based medicine)for the chemotherapy of advanced gallbladder caner, and it will be one of the important components in the large-scale clinical study of chemotherapy for the advanced gallbladder cancer in China and worldwide.